Tissue Protrusion after DES: Adverse Events at Long Term?

Original Title: Tissue Protrusion after Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy.

Reference: Fuyu Qiu et al. J Am Coll Cardiol Intv. 2016;9(14):1499-1507.

 

DESAfter DES implantation we may observe tissue protrusion (plaque or thrombus) relatively often, especially in unstable lesions; however, its clinical impact has not been studied. The aim of this study was to assess long term prevalence and clinical impact of tissue protrusion after DES implantation.

The ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) prospectively included 8,663 patients undergoing DES stenting.

In a pre-specified intravascular ultrasound (IVUS) substudy, 2,072 patients had post stenting IVUS and were classified according to presence or absence of post stenting tissue protrusion.

After stenting, 34.3% of lesions showed tissue protrusion by IVUS. Maximum tissue protrusion was 0.7 mm2 in area (range 0.5 to 1.2 mm) and 3 mm in length (range 1.4 to 6.7 mm).

Patients with tissue protrusion were often undergoing high risk ACS (STEMI and NSTEMI) and less often unstable angina or stable ischemic cardiomyopathy.

In 893 lesions studied by IVUS prior stenting, tissue protrusion was associated with larger proximal reference lumen area, greater plaque burden, and more plaque ruptures, attenuated plaque, and VH-thin cap fibroatheromas.

Because tissue protrusion often lead to post-dilation, these patients had a larger lumen area than patients without tissue protrusion.

At two year follow up, there was less clinically driven target lesion revascularization in patients with tissue protrusion and no significant difference in incidence of major adverse cardiac events (cardiac death, MI, or stent thrombosis) in patients with vs without tissue protrusion.

Conclusion

Tissue protrusion diagnosed by IVUS after DES stenting is not associated to adverse events in the long term, partly because of greater post dilation stent expansion.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....